Multisystem Inflammatory Syndrome in Children

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS withdrawal · 2025-10-31
Clinical Trial Update: Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)
Expanded access program using mesenchymal stromal cells to treat MIS-C associated with COVID-19 is no longer available.